{"id":8531,"date":"2026-01-03T11:28:28","date_gmt":"2026-01-03T16:28:28","guid":{"rendered":"https:\/\/www.curingheartdisease.com\/?p=8531"},"modified":"2026-07-16T10:59:30","modified_gmt":"2026-07-16T14:59:30","slug":"%e8%83%86%e5%9b%ba%e9%86%87%e5%a4%9a%e4%bd%8e%e6%89%8d%e7%ae%97%e8%bf%87%e4%bd%8e","status":"publish","type":"post","link":"https:\/\/www.curingheartdisease.com\/zh\/cholesterol-how-low-is-too-low\/","title":{"rendered":"\u80c6\u56fa\u9187\uff1a\u591a\u4f4e\u624d\u7b97\u592a\u4f4e\uff1f"},"content":{"rendered":"

Abstract<\/h3>\n

The management of low-density lipoprotein cholesterol (LDL-C) has transitioned into an intensive paradigm emphasizing sustained lowering, often summarized as \u201clower for longer.\u201dCentral to this shift is the therapeutic targeting of proprotein convertase subtilisin\/kexin type 9(PCSK9). While cardiovascular benefits are well-established, concerns regarding neurocognitive safety at extremely low LDL-C levels have persisted. This review synthesizes genetic,mechanistic, and clinical evidence addressing the relationship between PCSK9 modulation,lifelong lipid exposure, and neurodegenerative risk, specifically Alzheimer\u2019s disease (AD).<\/p>\n

\"\"<\/h3>\n

1. Introduction<\/h3>\n

The discovery of PCSK9 as a key regulator of LDL receptor (LDLR) density has revolutionized lipidology [1-3]. Monoclonal antibodies and gene-editing techniques targeting PCSK9 allow for LDL-C reductions exceeding 60%, often reaching levels below 20 mg\/dL [15]. Given the high cholesterol content of the brain, the safety of such profound systemic depletion remains acritical area of longitudinal analysis.<\/p>\n

2. Biochemical Regulation of the PCSK9 Axis<\/h3>\n

PCSK9 is a serine protease that binds to the epidermal growth factor-like repeat A (EGF-A) domain of the hepatic LDLR [2]. Under physiological conditions, this binding targets the receptor for lysosomal degradation, preventing its recycling to the cell surface and thereby increasing circulating LDL-C. Pharmacological inhibition\u2014via monoclonal antibodies or newer strategies like CRISPR-based base editing\u2014interrupts this interaction, restoring LDLR availability and enhancing LDL clearance from the plasma [3, 18].<\/p>\n

3. Genetic Variation and Lifelong Exposure<\/h3>\n

Human genetics provide a \u201cnatural experiment\u201d to assess long-term PCSK9 modulation. Loss-of-function (LoF) variants, such as the R46L variant common in European populations, lead to lifelong lower LDL-C and significant protection against atherosclerotic cardiovascular disease(ASCVD) [4-5]. Importantly, rare individuals with homozygous \u201cnull\u201d phenotypes exhibit LDL-Clevels as low as 15 mg\/dL without overt neurocognitive impairment, suggesting that systemicLDL-C depletion is compatible with normal human physiology [6].<\/p>\n

4. Brain Cholesterol Homeostasis and the Blood\u2013Brain Barrier<\/h3>\n

A critical mechanistic safeguard for neurocognitive health is the isolation of brain cholesterol metabolism. Approximately 25% of the body\u2019s cholesterol is located in the CNS, yet it is functionally separated from systemic pools by the blood\u2013brain barrier (BBB) [10]. Brain cholesterol is synthesized de novo primarily by astrocytes and neurons; it does not depend on circulating LDL-C particles [10]. Furthermore, monoclonal antibodies targeting PCSK9 are largemolecules that do not cross an intact BBB, precluding direct CNS interaction [1].<\/p>\n

5. Mendelian Randomization and Alzheimer\u2019s Risk<\/h3>\n

Early Mendelian Randomization (MR) studies raised speculative concerns regarding a possible increase in AD risk associated with lower LDL-C [9]. However, subsequent large-scale MR analyses involving over 115,000 individuals and higher-powered meta-analyses effectively refute these signals [9, 17]. Specifically, studies targeting LDL-C-lowering variants in the PCSK9 and HMGCR loci show a neutral odds ratio (OR \u2248 0.97) for AD, and some data suggest potential protective effects when non-HDL cholesterol is lowered over a lifetime [16-17].<\/p>\n

6. Clinical Trial Outcomes<\/h3>\n

Randomized controlled trials (RCTs) provide the most direct evidence of safety. The EBBINGHAUS study, a prospective neurocognitive substudy of the FOURIER trial, utilized objective cognitive testing in nearly 2,000 patients [11]. Over a median follow-up of 19 months,no differences were observed between evolocumab and placebo. Long-term extension data(FOURIER-OLE) reached follow-up durations of 7+ years, demonstrating sustained cognitivestability even among those achieving LDL-C levels < 20 mg\/dL [12, 15]. Similar safety profileshave been established for alirocumab in the ODYSSEY OUTCOMES trial and subsequent meta-analyses [13].<\/p>\n

7. Cardiovascular Benefits vs. Neurocognitive Neutrality<\/h3>\n

The log-linear relationship between LDL-C reduction and ASCVD risk reduction remains consistent across the therapeutic spectrum [14]. Clinical evidence suggests that the benefit of aggressive lowering continues without a plateau, while safety markers for dementia and cognitive decline remain flat [15].<\/p>\n

8. Conclusion<\/h3>\n

Comprehensive analysis of genetic epidemiology, mechanistic biology, and randomized clinical trials consistently supports the conclusion that PCSK9 inhibition and extremely low LDL-C do not increase the risk of Alzheimer\u2019s disease or other dementias. Local regulation of CNS cholesterol synthesis and BBB isolation provide a biological basis for systemic lipid management without neurocognitive consequence.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Katzmann JL, Gouni-Berthold I, Laufs U. PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects.\u00a0Front Physiol<\/i>. 2020;11:595819. Published 2020 Nov 16. doi:10.3389\/fphys.2020.595819<\/li>\n
  2. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade.\u00a0J Lipid Res<\/i>. 2012;53(12):2515-2524. doi:10.1194\/jlr.R026658<\/li>\n
  3. Seidah NG, Prat A, Pirillo A, Catapano AL, Norata GD. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.\u00a0Cardiovasc Res<\/i>. 2019;115(3):510-518. doi:10.1093\/cvr\/cvz003<\/li>\n
  4. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.\u00a0N Engl J Med<\/i>. 2006;354(12):1264-1272. doi:10.1056\/NEJMoa054013<\/li>\n
  5. Langsted A, Nordestgaard BG, Benn M, Tybj\u00e6rg-Hansen A, Kamstrup PR. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.\u00a0J Clin Endocrinol Metab<\/i>. 2016;101(9):3281-3287. doi:10.1210\/jc.2016-1206<\/li>\n
  6. Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation.\u00a0Nat Rev Cardiol<\/i>. 2019;16(3):155-165. doi:10.1038\/s41569-018-0107-8<\/li>\n
  7. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies.\u00a0Hum Mol Genet<\/i>. 2014;23(R1):R89-R98. doi:10.1093\/hmg\/ddu328<\/li>\n
  8. Larsson SC, Butterworth AS, Burgess S. Mendelian randomization for cardiovascular diseases: principles and applications.\u00a0Eur Heart J<\/i>. 2023;44(47):4913-4924. doi:10.1093\/eurheartj\/ehad736<\/li>\n
  9. Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybj\u00e6rg-Hansen A. Low LDL cholesterol,\u00a0PCSK9<\/i>\u00a0and\u00a0HMGCR<\/i>\u00a0genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study.\u00a0BMJ<\/i>. 2017;357:j1648. Published 2017 Apr 24. doi:10.1136\/bmj.j1648<\/li>\n
  10. Bj\u00f6rkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier.\u00a0Arterioscler Thromb Vasc Biol<\/i>. 2004;24(5):806-815. doi:10.1161\/01.ATV.0000120374.59826.1b<\/li>\n
  11. Giugliano RP, Mach F, Zavitz K, et al. Cognitive Function in a Randomized Trial of Evolocumab.\u00a0N Engl J Med<\/i>. 2017;377(7):633-643. doi:10.1056\/NEJMoa1701131<\/li>\n
  12. Zimerman A, O’Donoghue ML, Ran X, et al. Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab.\u00a0NEJM Evid<\/i>. 2025;4(1):EVIDoa2400112. doi:10.1056\/EVIDoa2400112<\/li>\n
  13. Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Alirocumab for the treatment of hypercholesterolemia.\u00a0Expert Opin Biol Ther<\/i>. 2017;17(5):633-643. doi:10.1080\/14712598.2017.1305354<\/li>\n
  14. Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.\u00a0Lancet<\/i>. 2010;376(9753):1670-1681. doi:10.1016\/S0140-6736(10)61350-5<\/li>\n
  15. Gaba P, O’Donoghue ML, Park JG, et al. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.\u00a0Circulation<\/i>. 2023;147(16):1192-1203. doi:10.1161\/CIRCULATIONAHA.122.063399<\/li>\n
  16. Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study.\u00a0J Am Coll Cardiol<\/i>. 2014;64(9):851-860. doi:10.1016\/j.jacc.2014.03.061<\/li>\n
  17. Tan JS, Hu MJ, Yang YM, Yang YJ. Genetic Predisposition to Low-Density Lipoprotein Cholesterol May Increase Risks of Both Individual and Familial Alzheimer’s Disease.\u00a0Front Med (Lausanne)<\/i>. 2022;8:798334. Published 2022 Jan 11. doi:10.3389\/fmed.2021.798334<\/li>\n
  18. Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.\u00a0Nature<\/i>. 2021;593(7859):429-434. doi:10.1038\/s41586-021-03534-y<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    LDL\u4f1a\u8fc7\u4f4e\u5417\uff1fPCSK9\u6291\u5236\u5242\u5bf9\u5927\u8111\u5065\u5eb7\u610f\u5473\u7740\u4ec0\u4e48<\/p>\n

    PCSK9\u6291\u5236\u5242\u662f\u76ee\u524d\u6700\u6709\u6548\u7684\u964d\u80c6\u56fa\u9187\u6cbb\u7597\u624b\u6bb5\u4e4b\u4e00\u3002\u5b83\u4eec\u80fd\u5c06\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\uff08\u201c\u574f\u80c6\u56fa\u9187\u201d\uff09\u964d\u4f4e50\u201360%\u751a\u81f3\u66f4\u591a\u2014\u2014\u5728\u67d0\u4e9b\u60c5\u51b5\u4e0b\uff0c\u8fd8\u80fd\u5c06\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u964d\u81f320 mg\/dL\u4ee5\u4e0b\u3002.<\/p>\n

    \u8fd9\u662f\u4e00\u79cd\u9884\u9632\u5fc3\u810f\u75c5\u53d1\u4f5c\u548c\u4e2d\u98ce\u7684\u7edd\u4f73\u5de5\u5177\u3002\u4f46\u5b83\u4e5f\u63d0\u51fa\u4e86\u4e00\u4e2a\u5408\u7406\u7684\u95ee\u9898\uff1a\u5982\u679c\u5927\u8111\u9700\u8981\u80c6\u56fa\u9187\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\uff08LDL\uff09\u4f1a\u4e0d\u4f1a\u201c\u8fc7\u4f4e\u201d\u4ece\u800c\u589e\u52a0\u60a3\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u6216\u75f4\u5446\u75c7\u7684\u98ce\u9669\u5462\uff1f<\/p>","protected":false},"author":16,"featured_media":8586,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[227,219,223,224],"tags":[],"class_list":["post-8531","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-apob-and-lipid-science","category-lipids-medications-and-testing","category-plaque-arteries-and-disease","category-regression-and-reversal"],"acf":[],"yoast_head":"\nCholesterol: How Low is Too Low? - The Premiere Heart Health Education Platform<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curingheartdisease.com\/zh\/\u80c6\u56fa\u9187\u591a\u4f4e\u624d\u7b97\u8fc7\u4f4e\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cholesterol: How Low is Too Low? - The Premiere Heart Health Education Platform\" \/>\n<meta property=\"og:description\" content=\"Can LDL Be Too Low? What PCSK9 Inhibitors Mean for Brain Health PCSK9 inhibitors are among the most powerful cholesterol-lowering treatments available. They can lower LDL (\u201cbad cholesterol\u201d) by 50\u201360% or more\u2014and in some cases drive LDL below 20 mg\/dL. That\u2019s an incredible tool for preventing heart attacks and strokes. But it also raises a fair question: If the brain needs cholesterol, could LDL get \u201ctoo low\u201d and increase the risk of Alzheimer\u2019s or dementia?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curingheartdisease.com\/zh\/\u80c6\u56fa\u9187\u591a\u4f4e\u624d\u7b97\u8fc7\u4f4e\/\" \/>\n<meta property=\"og:site_name\" content=\"The Premiere Heart Health Education Platform\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/curingheartdisease\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-03T16:28:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T14:59:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/01\/post-image-20.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Peter Megdal PhD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:site\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Peter Megdal PhD\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/\"},\"author\":{\"name\":\"Peter Megdal PhD\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\"},\"headline\":\"Cholesterol: How Low is Too Low?\",\"datePublished\":\"2026-01-03T16:28:28+00:00\",\"dateModified\":\"2026-07-16T14:59:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/\"},\"wordCount\":1107,\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/post-image-20.jpg\",\"articleSection\":[\"ApoB and Lipid Science\",\"Lipids, Medications and Testing\",\"Plaque, Arteries and Disease\",\"Regression and Reversal\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/\",\"name\":\"Cholesterol: How Low is Too Low? - The Premiere Heart Health Education Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/post-image-20.jpg\",\"datePublished\":\"2026-01-03T16:28:28+00:00\",\"dateModified\":\"2026-07-16T14:59:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/post-image-20.jpg\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/post-image-20.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cholesterol-how-low-is-too-low\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cholesterol: How Low is Too Low?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"name\":\"The Premiere Heart Health Education Platform\",\"description\":\"To make available to the public the state of the art information on how to reverse heart disease. This is an evidence-based organization utilizing the best available science, including diet, exercise drugs, and other resources to best fight this disease.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curingheartdisease.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\",\"name\":\"Curing Heart Disease, LLC\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"width\":512,\"height\":512,\"caption\":\"Curing Heart Disease, LLC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/curingheartdisease\",\"https:\\\/\\\/x.com\\\/RMHDInc\",\"https:\\\/\\\/www.instagram.com\\\/rmhdinc\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm8dh9c_D5RfJL7Z1f-yY4w\"],\"description\":\"Curing Heart Disease, LLC is an independent cardiovascular health education organization that publishes evidence-based articles, videos, podcasts, and educational tools about cardiovascular disease prevention, lipid science, nutrition, exercise, and related health topics.\",\"founder\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"foundingPerson\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"knowsAbout\":[\"Cardiovascular health\",\"Cardiovascular disease prevention\",\"Heart disease education\",\"Nutrition\",\"Exercise\",\"Lipid science\",\"Atherosclerosis\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\",\"givenName\":\"Peter\",\"familyName\":\"Megdal\",\"honorificSuffix\":\"PhD\",\"jobTitle\":\"Nutrition Researcher and Cardiovascular Health Educator\",\"description\":\"Peter Megdal, PhD, is a nutrition researcher, cardiovascular health educator, published researcher, and longtime competitive cyclist. He earned a PhD in nutrition from the University of Massachusetts and publishes evidence-based cardiovascular health education through Curing Heart Disease.\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\"},\"worksFor\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"affiliation\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"alumniOf\":{\"@type\":\"CollegeOrUniversity\",\"name\":\"University of Massachusetts\"},\"knowsAbout\":[\"Nutrition\",\"Cardiovascular health education\",\"Cardiovascular disease prevention\",\"Lipid science\",\"Exercise physiology\",\"Scientific research\"],\"sameAs\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/author\\\/peter-megdal\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/peter-megdal-56075a2\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u80c6\u56fa\u9187\uff1a\u591a\u4f4e\u624d\u7b97\u592a\u4f4e\uff1f\u2014\u2014\u9996\u5c48\u4e00\u6307\u7684\u5fc3\u810f\u5065\u5eb7\u6559\u80b2\u5e73\u53f0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curingheartdisease.com\/zh\/\u80c6\u56fa\u9187\u591a\u4f4e\u624d\u7b97\u8fc7\u4f4e\/","og_locale":"zh_CN","og_type":"article","og_title":"Cholesterol: How Low is Too Low? - The Premiere Heart Health Education Platform","og_description":"Can LDL Be Too Low? What PCSK9 Inhibitors Mean for Brain Health PCSK9 inhibitors are among the most powerful cholesterol-lowering treatments available. They can lower LDL (\u201cbad cholesterol\u201d) by 50\u201360% or more\u2014and in some cases drive LDL below 20 mg\/dL. That\u2019s an incredible tool for preventing heart attacks and strokes. But it also raises a fair question: If the brain needs cholesterol, could LDL get \u201ctoo low\u201d and increase the risk of Alzheimer\u2019s or dementia?","og_url":"https:\/\/www.curingheartdisease.com\/zh\/\u80c6\u56fa\u9187\u591a\u4f4e\u624d\u7b97\u8fc7\u4f4e\/","og_site_name":"The Premiere Heart Health Education Platform","article_publisher":"https:\/\/www.facebook.com\/curingheartdisease","article_published_time":"2026-01-03T16:28:28+00:00","article_modified_time":"2026-07-16T14:59:30+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/01\/post-image-20.jpg","type":"image\/jpeg"}],"author":"Peter Megdal PhD","twitter_card":"summary_large_image","twitter_creator":"@RMHDInc","twitter_site":"@RMHDInc","twitter_misc":{"\u4f5c\u8005":"Peter Megdal PhD","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"6 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/#article","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/"},"author":{"name":"Peter Megdal PhD","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53"},"headline":"Cholesterol: How Low is Too Low?","datePublished":"2026-01-03T16:28:28+00:00","dateModified":"2026-07-16T14:59:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/"},"wordCount":1107,"publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/01\/post-image-20.jpg","articleSection":["ApoB and Lipid Science","Lipids, Medications and Testing","Plaque, Arteries and Disease","Regression and Reversal"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/","url":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/","name":"\u80c6\u56fa\u9187\uff1a\u591a\u4f4e\u624d\u7b97\u592a\u4f4e\uff1f\u2014\u2014\u9996\u5c48\u4e00\u6307\u7684\u5fc3\u810f\u5065\u5eb7\u6559\u80b2\u5e73\u53f0","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/#primaryimage"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/01\/post-image-20.jpg","datePublished":"2026-01-03T16:28:28+00:00","dateModified":"2026-07-16T14:59:30+00:00","breadcrumb":{"@id":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/#primaryimage","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/01\/post-image-20.jpg","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/01\/post-image-20.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.curingheartdisease.com\/cholesterol-how-low-is-too-low\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curingheartdisease.com\/"},{"@type":"ListItem","position":2,"name":"Cholesterol: How Low is Too Low?"}]},{"@type":"WebSite","@id":"https:\/\/www.curingheartdisease.com\/#website","url":"https:\/\/www.curingheartdisease.com\/","name":"\u9996\u9009\u5fc3\u810f\u5065\u5eb7\u6559\u80b2\u5e73\u53f0","description":"\u5411\u516c\u4f17\u63d0\u4f9b\u5173\u4e8e\u5982\u4f55\u9006\u8f6c\u5fc3\u810f\u75c5\u7684\u6700\u65b0\u524d\u6cbf\u4fe1\u606f\u3002\u8fd9\u662f\u4e00\u4e2a\u57fa\u4e8e\u8bc1\u636e\u7684\u7ec4\u7ec7\uff0c\u5229\u7528\u73b0\u6709\u7684\u6700\u4f73\u79d1\u5b66\u6210\u679c\uff0c\u5305\u62ec\u996e\u98df\u3001\u8fd0\u52a8\u3001\u836f\u7269\u548c\u5176\u4ed6\u8d44\u6e90\uff0c\u4ee5\u6700\u597d\u5730\u5bf9\u6297\u8fd9\u79cd\u75be\u75c5\u3002.","publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curingheartdisease.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/www.curingheartdisease.com\/#organization","name":"\u6cbb\u6108\u5fc3\u810f\u75c5\u6709\u9650\u8d23\u4efb\u516c\u53f8","url":"https:\/\/www.curingheartdisease.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","width":512,"height":512,"caption":"Curing Heart Disease, LLC"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/curingheartdisease","https:\/\/x.com\/RMHDInc","https:\/\/www.instagram.com\/rmhdinc\/","https:\/\/www.youtube.com\/channel\/UCm8dh9c_D5RfJL7Z1f-yY4w"],"description":"\u6cbb\u6108\u5fc3\u810f\u75c5\u6709\u9650\u8d23\u4efb\u516c\u53f8\u662f\u4e00\u5bb6\u72ec\u7acb\u7684 \u5fc3\u8840\u7ba1\u5065\u5eb7\u6559\u80b2\u673a\u6784\uff0c\u81f4\u529b\u4e8e\u53d1\u5e03\u5173\u4e8e\u5fc3\u8840\u7ba1\u75be\u75c5\u9884\u9632\u3001\u8102\u8d28\u79d1\u5b66\u3001\u8425\u517b\u3001\u8fd0\u52a8\u53ca\u76f8\u5173\u5065\u5eb7\u4e3b\u9898\u7684\u5faa\u8bc1\u6587\u7ae0\u3001\u89c6\u9891\u3001\u64ad\u5ba2\u548c\u6559\u80b2\u5de5\u5177\u3002.","founder":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"foundingPerson":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"knowsAbout":["Cardiovascular health","Cardiovascular disease prevention","Heart disease education","Nutrition","Exercise","Lipid science","Atherosclerosis"]},{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD","url":"https:\/\/www.curingheartdisease.com\/peters-story\/","givenName":"Peter","familyName":"Megdal","honorificSuffix":"PhD","jobTitle":"Nutrition Researcher and Cardiovascular Health Educator","description":"Peter Megdal, PhD \u662f\u4e00\u4f4d\u8425\u517b\u5b66\u7814\u7a76\u5458\u3001\u5fc3\u8840\u7ba1\u5065\u5eb7\u6559\u80b2\u8005\u3001\u53d1\u8868\u8fc7\u7814\u7a76\u6210\u679c\u7684\u5b66\u8005\uff0c\u540c\u65f6\u4e5f\u662f\u4e00\u540d\u8d44\u6df1\u7ade\u6280\u81ea\u884c\u8f66\u624b\u3002\u4ed6\u62e5\u6709\u9a6c\u8428\u8bf8\u585e\u5927\u5b66\u8425\u517b\u5b66\u535a\u58eb\u5b66\u4f4d\uff0c\u5e76\u901a\u8fc7\u201cCuring Heart Disease\u201d\u5e73\u53f0\u53d1\u5e03\u57fa\u4e8e\u8bc1\u636e\u7684\u5fc3\u8840\u7ba1\u5065\u5eb7\u6559\u80b2\u5185\u5bb9\u3002.","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/peters-story\/"},"worksFor":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"affiliation":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"alumniOf":{"@type":"CollegeOrUniversity","name":"University of Massachusetts"},"knowsAbout":["Nutrition","Cardiovascular health education","Cardiovascular disease prevention","Lipid science","Exercise physiology","Scientific research"],"sameAs":["https:\/\/www.curingheartdisease.com\/author\/peter-megdal\/","https:\/\/www.linkedin.com\/in\/peter-megdal-56075a2\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/posts\/8531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/comments?post=8531"}],"version-history":[{"count":27,"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/posts\/8531\/revisions"}],"predecessor-version":[{"id":12116,"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/posts\/8531\/revisions\/12116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/media\/8586"}],"wp:attachment":[{"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/media?parent=8531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/categories?post=8531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/zh\/wp-json\/wp\/v2\/tags?post=8531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}